Literature DB >> 31704135

Denosumab for giant cell tumour of bone: success and limitations.

John H Healey1.   

Abstract

Entities:  

Year:  2019        PMID： 31704135     DOI： 10.1016/S1470-2045(19)30660-6

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  4 in total

1.  Malignant Transformation of Giant Cell Tumor of Bone and the Association with Denosumab Treatment: A Radiology and Pathology Perspective.

Authors:  K van Langevelde; A H G Cleven; A Navas Cañete; L van der Heijden; M A J van de Sande; H Gelderblom; J V M G Bovée
Journal:  Sarcoma       Date:  2022-06-17

2.  Malignancy in giant cell tumor of bone: analysis of an open-label phase 2 study of denosumab.

Authors:  Emanuela Palmerini; Leanne L Seeger; Marco Gambarotti; Alberto Righi; Peter Reichardt; Susan Bukata; Jean-Yves Blay; Tian Dai; Danielle Jandial; Piero Picci
Journal:  BMC Cancer       Date:  2021-01-22       Impact factor: 4.430

3.  Anti-IL17 antibody Secukinumab therapy is associated with ossification in giant cell tumor of bone: a case report of pathologic similarities and therapeutic potential similar to Denosumab.

Authors:  Andrew Chandler; Meredith K Bartelstein; Tomohiro Fujiwara; Cristina R Antonescu; John H Healey; Max Vaynrub
Journal:  BMC Musculoskelet Disord       Date:  2021-04-01       Impact factor: 2.362

4.  Tumor microenvironment in giant cell tumor of bone: evaluation of PD-L1 expression and SIRPα infiltration after denosumab treatment.

Authors:  Yu Toda; Kenichi Kohashi; Hidetaka Yamamoto; Shin Ishihara; Yoshihiro Ito; Yosuke Susuki; Kengo Kawaguchi; Daisuke Kiyozawa; Dai Takamatsu; Izumi Kinoshita; Yuichi Yamada; Junki Maehara; Atsushi Kimura; Sadafumi Tamiya; Kenichi Taguchi; Tomoya Matsunobu; Yoshihiro Matsumoto; Yasuharu Nakashima; Masaaki Mawatari; Yoshinao Oda
Journal:  Sci Rep       Date:  2021-07-20       Impact factor: 4.379
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.